About US
Contact us
-
Credit Suisse says Pfizer patent win will discourage 'at-risk' launchesWill Pfizer's ($PFE) big patent win against Teva Pharmaceutical Industries ($TEVA) and India'sSun PharmaonProtonixdiscourage more "at-risk" drug launches of generics in the U.S.? Credit Suisse thinks2013/6/14
-
UPDATED: GSK probes sales tactics in China days after firing R&D chief thereSales scandals are breaking out around the world for Big Pharma. Novartis ($NVS) acknowledged this week it had terminated some sales execs in India as it probes unethical practices there, and now Glax2013/6/14
-
Sales upside for Sanofi's Fluzone Quadrivalent looks strongThe FDA two days ago gave its approval to Sanofi's ($SNY)Fluzone Quadrivalent, a 4-in-1influenzavaccine, and now the estimates on the revenue upside are starting to roll in. GlobalData says they look2013/6/13
-
PDL, Roche duke it out over royalties for Avastin, HerceptinEven friends have disputes over money sometimes. That's what's happening withPDL BioPharmaand Roche's ($RHHBY)Genentech: PDL wants to take Genentech to arbitration for underpaying royalties, theAPrepo2013/6/13
-
Royalty tries to seal the deal with bid for Elan that could be worth $8BElan ($ELN) and Royalty Pharmahave been in a rapid back-and-forth of one-upmanship to win the hearts and votes of Elan shareholders. But the latest offer from Royalty may turn the tide. Royalty wants2013/6/9
-
UPDATED: FDA advisers vote for looser reins on GlaxoSmithKline's AvandiaIt took multiple tries and a vote tallied on paper to make sure everything was correct, but finally, we have a verdict. After two days of hearings, on Thursday an advisory panel recommended the FDA ke2013/6/9
-
Sanofi uses multi-pronged strategy to defend its place in diabetes marketLantusis the best-selling diabetes drug in the world right now, hitting $6.674 billion last year. It is also the top-selling drug for Sanofi ($SNY). But the French drugmaker is not letting all of that2013/6/8
-
India's largest pharmacy group halts sales of Ranbaxy drugsBad news just keeps raining down onRanbaxy Laboratories. The Indian generics maker thought it had finally left its problems with U.S. regulators behind after its felony pleas and $500 million penalty2013/6/8
-
Scientists reveal malaria’s deadly binding mechanismThe binding mechanism that allows red blood cells infected with aggressive strains of malaria to stick to blood vessels has been discovered in a new study on children in Tanzania. Researchers from th2013/6/7
-
FDA official, panelists challenge Avandia safety trialDr. Thomas Marciniak, medical team leader of FDA's Division of Cardiovascular and Renal Products, made some expensive promises Wednesday morning. Before a panel of outside experts tasked with advising2013/6/7